FREMONT, Calif., Feb. 3 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX) today announced that it will present at the Merrill Lynch
Global Pharmaceutical, Biotechnology & Medical Device Conference on Thursday,
February 10, 2005 at 7:30 a.m. PT / 10:30 a.m. ET. The presentation will be
webcast live and may be accessed by visiting the Abgenix website at
http://www.abgenix.com. A replay of the webcast will also be available on the
company's website until Thursday, February 24, 2005.
Bill Ringo, president and chief executive officer of Abgenix, will provide
an update on the company's antibody drug development activities.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and
state-of-the-art manufacturing capabilities that enable the rapid generation,
selection and production of high affinity, fully human antibody product
candidates to a variety of disease targets. Abgenix leverages its leadership
position in human antibody technology to build a diversified product portfolio
through the establishment of collaborations with multiple pharmaceutical and
biotechnology companies. For more information on Abgenix, visit the company's
website at http://www.abgenix.com.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Ami Knoefler, Director, Corporate
Communications, of Abgenix, Inc., +1-510-284-6350, or
+1-510-284-6605
|
